Discounted Cash Flow Rating

Strong Sell

Return on Equity Rating

Strong Buy

Debt to Equity Rating

Strong Buy

Price to Earnings Rating

Neutral

Analyst Rating

Buy

Valneva SE American Depositary Shares (VALN)

https://www.valneva.com

Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes two vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, & third-party products; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The majority is from the Commercialized vaccines segment & geographically from the United States.

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

05/06/2021

Market Cap

539,787,153

Shares Outstanding

138,900,000

Weighted SO

69,393,910

Total Employees

N/A

Upcoming Earnings

09/19/2024

Beta

0.9710

Last Div

0.0000

Range

6.39-14.94

Chg

-0.0818

Avg Vol

7224

Mkt Cap

539787153

Exch

NASDAQ

Country

FR

Phone

33 2 28 07 37 10

DCF Diff

13.8431

DCF

-6.0031

Div Yield

0.0000

P/S

3.2502

EV Multiple

-6.0550

P/FV

5.8792

Div Yield %

0.0000

P/E

-30.1656

PEG

-3.5739

Payout

0.0000

Current Ratio

2.6262

Quick Ratio

2.1494

Cash Ratio

1.2822

DSO

73.8773

DIO

192.4832

Op Cycle

266.3605

DPO

33.5832

CCC

232.7772

Gross Margin

0.3854

Op Margin

-0.6774

Pretax Margin

-0.1723

Net Margin

-0.2149

Eff Tax Rate

-0.2470

ROA

-0.0695

ROE

-0.2021

ROCE

-0.2806

NI/EBT

1.2470

EBT/EBIT

0.2544

EBIT/Rev

-0.6774

Debt Ratio

0.3925

D/E

1.1012

LT Debt/Cap

0.4912

Total Debt/Cap

0.5241

Int Coverage

-3.8652

CF/Debt

-1.1842

Equity Multi

2.8060

Rec Turnover

4.9406

Pay Turnover

10.8685

Inv Turnover

1.8963

FA Turnover

0.9634

Asset Turnover

0.3232

OCF/Share

-1.5623

FCF/Share

-1.6439

Cash/Share

0.9469

OCF/Sales

-1.4380

FCF/OCF

1.0522

CF Coverage

-1.1842

ST Coverage

-9.6122

CapEx Coverage

-19.1564

Div&CapEx Cov

-19.1564

P/BV

5.8792

P/B

5.8792

P/S

3.2502

P/E

-30.1656

P/FCF

-2.1480

P/OCF

-4.5085

P/CF

-4.5085

PEG

-3.5739

P/S

3.2502

EV Multiple

-6.0550

P/FV

5.8792

DPS

0.0000

Latest Headlines (EST)

GlobeNewswire Inc. Jun 26, 05:00 Valneva Announces Exclusive Vaccine Marketing and Distribution Agreement for Germany with CSL Seqirus GlobeNewswire Inc. Jun 26, 05:00 Valneva annonce un accord exclusif avec CSL Seqirus pour le marketing et la distribution de ses vaccins en Allemagne GlobeNewswire Inc. Jun 05, 05:30 [Valneva SE] Declaration of shares and voting rights - May 2025 GlobeNewswire Inc. Jun 05, 05:30 [Valneva SE] Déclaration d’actions et de droits de vote - mai 2025 GlobeNewswire Inc. Apr 26, 17:10 Valneva Provides Update on Recommendation for Use of Its Chikungunya Vaccine by French Authorities GlobeNewswire Inc. Apr 26, 17:10 Valneva fait un point sur la recommandation d’utilisation de son vaccin contre le chikungunya par les autorités françaises GlobeNewswire Inc. Apr 25, 20:54 INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Teleflex Incorporated - TFX GlobeNewswire Inc. Apr 22, 22:42 Valneva SE Company Investigated by the Portnoy Law Firm GlobeNewswire Inc. Apr 22, 22:38 Robinhood Markets, Inc. Investors: Company Investigated by the Portnoy Law Firm GlobeNewswire Inc. Apr 09, 05:00 Valneva et LimmaTech annoncent la vaccination du premier participant à l’étude pédiatrique de Phase 2 du candidat vaccin tétravalent contre la shigellose S4V2 GlobeNewswire Inc. Apr 09, 05:00 Valneva and LimmaTech Announce First Vaccination in Phase 2 Infant Study of Tetravalent Shigella Vaccine Candidate S4V2 GlobeNewswire Inc. Mar 24, 06:00 Valneva répond à l'appel du gouvernement français pour la fourniture du vaccin IXCHIQ® contre l'épidémie de chikungunya à La Réunion GlobeNewswire Inc. Mar 24, 06:00 Valneva Responds to French Government’s Call for Vaccine Supply of IXCHIQ® against Chikungunya Outbreak in La Réunion GlobeNewswire Inc. Nov 12, 06:00 Valneva fera des présentations et rencontrera les investisseurs lors de conférences aux États-Unis et en Europe GlobeNewswire Inc. Oct 04, 05:30 Valneva SE - Declaration of shares and voting rights - September 30, 2024 Benzinga Nov 10, 14:00 Analyst Ratings for Valneva

Revenue Product Segmentation